Antiviral activity of selected nucleoside analogues against human herpes virus type 6

Reymen, D.; Naesens, Lieve; Balzarini, Jan; Holy, A.; Clercq, E. De

doi:10.1016/0166-3542(95)94887-8

Cited by 4 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Acyclic analogues of 7‐deazapurine nucleosides and nucleotides were also screened for antiviral activities but generally these compounds showed only poor activities, especially when compared with the corresponding purine analogues . Nevertheless, some acyclic analogues of 7‐bromo‐7‐deazaadenosine ( 81a‐b ) and thiosangivamycin ( 82a‐b ) possess selective activity against human cytomegalovirus that is comparable or better than that of ganciclovir.…”

Section: Nucleosides With Antiviral Activitiesmentioning

confidence: 99%

Pyrrolo[2,3‐d]pyrimidine (7‐deazapurine) as a privileged scaffold in design of antitumor and antiviral nucleosides

Perlíková

Hocek

2017

Medicinal Research Reviews

View full text Add to dashboard Cite

Abstract7‐Deazapurine (pyrrolo[2,3‐d]pyrimidine) nucleosides are important analogues of biogenic purine nucleosides with diverse biological activities. Replacement of the N7 atom with a carbon atom makes the five‐membered ring more electron rich and brings a possibility of attaching additional substituents at the C7 position. This often leads to derivatives with increased base‐pairing in DNA or RNA or better binding to enzymes. Several types of 7‐deazapurine nucleosides with potent cytostatic or cytotoxic effects have been identified. The most promising are 7‐hetaryl‐7‐deazaadenosines, which are activated in cancer cells by phosphorylation and get incorporated both to RNA (causing inhibition of proteosynthesis) and to DNA (causing DNA damage). Mechanism of action of other types of cytostatic nucleosides, 6‐hetaryl‐7‐deazapurine and thieno‐fused deazapurine ribonucleosides, is not yet known. Many 7‐deazaadenosine derivatives are potent inhibitors of adenosine kinases. Many types of sugar‐modified derivatives of 7‐deazapurine nucleosides are also strong antivirals. Most important are 2′‐C‐methylribo‐ or 2′‐C‐methyl‐2′‐fluororibonucleosides with anti‐HCV activities (several compounds underwent clinical trials). Some underexplored areas of potential interest are also outlined.

show abstract

Section: Nucleosides With Antiviral Activitiesmentioning

confidence: 99%

Pyrrolo[2,3‐d]pyrimidine (7‐deazapurine) as a privileged scaffold in design of antitumor and antiviral nucleosides

Perlíková

Hocek

2017

Medicinal Research Reviews

View full text Add to dashboard Cite

show abstract

“…Adefovir {9‐[2‐(phosphonylmethoxy)ethyl]adenine, PMEA} was the first nucleotide analogue developed for the treatment of HIV infection [1]. Its active intracellular metabolite, adefovir diphosphate, is a potent inhibitor not only of HIV reverse transcriptase in vitro but also of herpesvirus and hepatitis B DNA polymerase [2–4]. Low bioavailability led to the synthesis of several prodrugs; adefovir dipivoxil (bisPOM PMEA) was selected for clinical development because of its pharmacokinetic profile, including a long half‐life allowing once daily dosing.…”

Section: Introductionmentioning

confidence: 99%

A randomized placebo‐controlled trial of adefovir dipivoxil in advanced HIV infection: the ADHOC trial

Reiss¹

2002

HIV Medicine

View full text Add to dashboard Cite

show abstract

Cidofovir, a New Agent with Potent Anti-Herpesvirus Activity

Hitchcock

Jaffe

Martin

et al. 1996

Antivir Chem Chemother

137

View full text Add to dashboard Cite

SummaryCidofovir is a potent, broad spectrum antiviral agent with activity in vitro and in vivo against cytomegalovirus and other members of the herpesvirus family, as well as certain other DNA viruses. After uptake into cells it is converted enzymatically to cidofovir diphosphate, a structural analogue of deoxycytidine triphosphate, which selectively inhibits viral DNA polymerases relative to host cell polymerases. Cross-resistance to cidofovir is not usually seen with human cytomegalovirus isolates that are foscarnet-resistant, or isolates that are ganciclovir-resistant due to a deficiency in ganciclovir phosphorylation. Cross-resistance is seen, however, with isolates that are ganciclovir resistant due to polymerase mutations. A prolonged elimination phase seen in vivo, correlates with a long intracellular half-life seen in vitro and allows for efficacy in-animal models of virus infection with infrequent dosing or prophylaxis. Clinical studies of intravenous cidofovir in cytomegalovirus retinitis in patients with AIDS are claimed to show delay of retinitis progression with maintenance doses given once every 2 weeks.

show abstract

Antiviral activity of selected nucleoside analogues against human herpes virus type 6

Cited by 4 publications

References 0 publications

Pyrrolo[2,3‐d]pyrimidine (7‐deazapurine) as a privileged scaffold in design of antitumor and antiviral nucleosides

Pyrrolo[2,3‐d]pyrimidine (7‐deazapurine) as a privileged scaffold in design of antitumor and antiviral nucleosides

A randomized placebo‐controlled trial of adefovir dipivoxil in advanced HIV infection: the ADHOC trial

Cidofovir, a New Agent with Potent Anti-Herpesvirus Activity

Contact Info

Product

Resources

About